News
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug to meet a significant ...
Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by i ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback